Table 2. Observed (Obs) and expected (Exp) numbers of cancers in person HIV or with AIDS, SIR, and corresponding 95% CI by time of diagnosis and overall. Italy, 1985–1998.
|
60–25 months before AIDS |
24–7 months before AIDS |
6 months before to 3 months after AIDSa |
4–42 months after AIDS |
Total |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD10, cancer type or site | Obs | SIR | (95% CI) | Obs | SIR | (95% CI) | Obs | SIR | (95% CI) | Obs | SIR | (95% CI) | Obs | Exp | SIR | (95% CI) |
| Person years | 27 882 | 14 652 | 7491 | 10 397 | 60 421 | |||||||||||
| C46, KS | 406 | 6667 | (6034–7348) | 119 | 497 | (412–595) | 525 | 0.30 | 1749 | (1602–1905) | ||||||
| C82–C85, NHL | 322 | 1229 | (1098–1371) | 127 | 125 | (105–149) | 449 | 1.27 | 352 | (320–386) | ||||||
| C53, ICC | 1 | 3.0 | (0.0–17.5) | 2 | 9.6 | (0.9–35.4) | 14 | 121.2 | (66–204) | 1 | 5.8 | (0.0–33.1) | 18 | 0.82 | 21.8 | (12.9–34.6) |
| C16, Stomach | 1 | 0.6 | (0.0–3.7) | 1 | 1.1 | (0.0–6.2) | 4 | 8.1 | (2.1–21.1) | 2 | 3.3 | (0.3–12.2) | 8 | 3.56 | 2.2 | (1.0–4.4) |
| C18, Colon | 0 | 0 | — | 2 | 1.8 | (0.2–6.6) | 1 | 1.6 | (0.0–9.4) | 1 | 1.3 | (0.0–7.5) | 4 | 4.21 | 0.9 | (0.2–2.5) |
| C20, Rectum | 0 | 0 | — | 1 | 1.7 | (0.0–10.0) | 2 | 6.5 | (0.6–23.9) | 2 | 5.2 | (0.5–19.0) | 5 | 2.18 | 2.3 | (0.7–5.4) |
| C21, Anus | 3 | 44.4 | (8.4–131.4) | 0 | 0 | — | 1 | 38.5 | (0.0–220.9) | 2 | 51.5 | (4.9–189.2) | 6 | 0.18 | 33.6 | (12.1–73.6) |
| C22, Liver | 0 | 0 | — | 0 | 0 | — | 1 | 4.3 | (0.0–24.6) | 2 | 6.9 | (0.7–25.5) | 3 | 1.58 | 1.9 | (0.4–5.6) |
| C25, Pancreas | 0 | 0 | — | 0 | 0 | — | 1 | 5.5 | (0.0–31.4) | 1 | 4.4 | (0.0–25.1) | 2 | 1.27 | 1.6 | (0.1–5.8) |
| C32, Larynx | 0 | 0 | — | 0 | 0 | — | 1 | 3.7 | (0.0–21.0) | 1 | 3.0 | (0.0–17.3) | 2 | 1.95 | 1.0 | (0.1–3.8) |
| C33–C34, Trachea and lung | 1 | 0.3 | (0.0–1.5) | 0 | 0 | — | 13 | 10.3 | (5.5–17.7) | 8 | 5.4 | (2.3–10.8) | 22 | 9.02 | 2.4 | (1.5–3.7) |
| C43, Melanoma | 0 | 0 | — | 1 | 1.1 | (0.0–6.1) | 2 | 3.9 | (0.4–14.3) | 0 | 0 | — | 3 | 3.72 | 0.8 | (0.2–2.4) |
| C44, Skin | 3 | 0.8 | (0.2–2.4) | 5 | 2.1 | (0.7–4.9) | 3 | 2.3 | (0.4–6.7) | 3 | 1.7 | (0.3–4.9) | 14 | 9.28 | 1.5 | (0.8–2.5) |
| C50, Breastb | 0 | 0 | — | 3 | 2.6 | (0.5–7.8) | 0 | 0 | — | 0 | 0 | — | 3 | 4.43 | 0.7 | (0.1–2.0) |
| C56, Ovary | 0 | 0 | — | 0 | 0 | — | 3 | 33.1 | (6.2–98.1) | 0 | 0 | — | 3 | 0.68 | 4.4 | (0.8–13.2) |
| C61, Prostate | 0 | 0 | — | 1 | 2.1 | (0.0–11.8) | 0 | 0 | — | 1 | 3.1 | (0.0–17.6) | 2 | 1.72 | 1.2 | (0.1–4.3) |
| C62, Testis | 0 | 0 | — | 4 | 4.3 | (1.1–11.2) | 0 | 0 | — | 0 | 0 | — | 4 | 3.73 | 1.1 | (0.3–2.8) |
| C64, Kidney | 1 | 0.9 | (0.0–5.0) | 1 | 1.4 | (0.0–8.0) | 1 | 2.6 | (0.0–14.8) | 0 | 0 | — | 3 | 2.75 | 1.1 | (0.2–3.2) |
| C67, Bladder | 0 | 0 | — | 1 | 0.8 | (0.0–4.5) | 0 | 0 | — | 1 | 1.2 | (0.0–7.0) | 2 | 4.80 | 0.4 | (0.0–1.5) |
| C70–C72, Brain | 0 | 0 | — | 0 | 0 | — | 8 | 24.3 | (10.4–48.0) | 3 | 6.6 | (1.2–19.5) | 11 | 2.48 | 4.4 | (2.2–8.0) |
| C81, Hodgkin's disease | 6 | 4.6 | (1.6–10.0) | 12 | 17.9 | (9.2–31.4) | 19 | 56.3 | (33.8–88.1) | 8 | 17.6 | (7.5–34.8) | 45 | 2.77 | 16.2 | (11.8–21.7) |
| C90, Myeloma | 0 | 0 | — | 1 | 6.0 | (0.0–34.5) | 0 | 0 | — | 2 | 16.6 | (1.6–61.0) | 3 | 0.62 | 4.8 | (0.9–14.3) |
| C91–C95, Leukaemia, all | 1 | 0.9 | (0.0–5.4) | 3 | 4.9 | (0.9–14.4) | 6 | 18.5 | (6.7–40.5) | 3 | 6.9 | (1.3–20.4) | 13 | 2.44 | 5.3 | (2.8–9.2) |
| C91, Leukaemia, lymphoid | 1 | 2.7 | (0.0–15.2) | 0 | 0 | — | 4 | 34.0 | (8.8–87.8) | 0 | 0 | — | 5 | 0.87 | 5.7 | (1.8–13.5) |
| C92, Leukaemia, myeloid | 0 | 0 | — | 2 | 5.7 | (0.5–21.0) | 1 | 5.4 | (0.0–30.9) | 2 | 7.9 | (0.7–29.2) | 5 | 1.39 | 3.6 | (1.1–8.4) |
| All non-AIDS defining cancerc | 18 | 0.6 | (0.3–0.9) | 39 | 2.0 | (1.4–2.8) | 68 | 6.6 | (5.1–8.4) | 45 | 3.3 | (2.4–4.5) | 170 | 74.48 | 2.3 | (2.0–2.7) |
SIR=Standardized Incidence Ratios; CI=Confidence Intervals; KS=Kaposi's Sacroma; NHL=Non-Hodgkin Lymphoma; ICC=Invasive Cervical Cancer.
a
For KS and NHL: from AIDS to 3 months after.
b
Females only.
c
It includes neoplasms excluding KS, NHL and ICC plus one of each: lip; nasopharynx; digestive organs, not otherwise specified; nasal cavity; mediastinum; connective tissue; retroperitoneum; vulva; corpus uteri; uterus, not otherwise specified; penis; endocrine glands; and unknown primary site.